echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > [JAMA] Plasma therapy during rehabilitation is not effective for critically ill patients with COVID-19? Come and see what the scientists say

    [JAMA] Plasma therapy during rehabilitation is not effective for critically ill patients with COVID-19? Come and see what the scientists say

    • Last Update: 2021-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This article is original by Translational Medicine.
    Please indicate the source for reprinting.
    Author: Tiffany Guide: The plasma of recovered patients is effective against the new coronavirus
    .

    When the new type of coronavirus invades the human body, some people with strong immunity will produce corresponding antibodies to eliminate the virus, and the plasma of the recovered will contain this antibody
    .

    At present, there are no specific drugs for the treatment of the new coronavirus, but the plasma of the recovered patients contains antibodies, which is an effective method for the treatment of the new coronavirus
    .

    But not all people are suitable for plasma therapy for survivors.
    Recently, scientists have discovered that for critically ill patients, this treatment is not effective for them.
    .
    .
    In the first few days of the COVID-19 pandemic, the medical community Adopted
    .

    Their hypothesis is that in the so-called "convalescent plasma", components that have previously fought against this disease may fight against this disease again, and this component has played a role in other diseases such as Ebola
    .

    Today, an international research team including doctors and scientists at the University of Pittsburgh School of Medicine and patients at the University of Pittsburgh School of Medicine has verified the ineffectiveness of this approach through a clinical trial, which concluded that COVID-19 treats most critically ill patients For treatment, the plasma is "ineffective" during the recovery period
    .

    The results of the study were published in the "JAMA" magazine and also at the annual meeting of the European Society of Critical Care Medicine
    .

    Co-author Bryan McVery is an associate professor in the field of lung, allergy, and critical care medicine at the University of Pittsburgh and a critical care medical scientist at the University of Pittsburgh School of Medicine.
    He explained: “In the early days of the pandemic, when thousands of people were sick, treatments had not yet been discovered.
    At that time, there are biologically reasonable reasons to switch to convalescent plasma.
    Unfortunately, it is either performed outside of clinical trials or in trials that do not focus on critically ill patients, which slows us down to see if it is true Effective capabilities
    .

    Finally, with these results, we can stop using convalescent plasma for the most severely ill patients with new coronary pneumonia, focusing on the treatments we know effective, and developing and testing better treatments
    .

    "These findings are REMAP -The latest discovery of CAP (randomized, embedded, multi-factor, adaptive community-acquired pneumonia platform trial), which recruited thousands of patients from hundreds of hospitals around the world to quickly determine which new coronary pneumonia treatments are most effective for which patients Effective
    .

    To date, more than 400 patients from the University of Pittsburgh School of Medicine have been included in the study
    .

    In its findings, REMAP-CAP showed that cheap steroids are effective in helping critically ill patients, while blood thinners help moderate patients
    .

    In the recovery plasma test, REMAP-CAP registered 2011 hospitalized adults with severe COVID-19
    .

    They were randomly divided into two groups, one group received two units of recovery plasma, the other group did not receive plasma, and then observed whether the possibility of surviving for at least three weeks without organ support (such as a ventilator) is due to whether It's different depending on the treatment
    .

    When enough data was collected to show that the convalescent plasma was not helpful for critically ill COVID-19 patients with a certainty of more than 99%, the trial concluded that it was invalid
    .

    However, the results of 126 immunocompromised patients were slightly different
    .

    Compared with standard treatment, the performance of the convalescent plasma treatment group was slightly better, but the number of patients was too small to make a clear conclusion
    .

    Corresponding author Lise Estcourt is a doctor of medicine.
    He is also an associate professor of hematology and transfusion medicine at the Radcliffe Department of Medicine at Oxford University and the director of the Department of Blood and Transplantation Clinical Trials at the National Health Service.
    He explained: "Maybe the immune system is impaired, Patients who are unable to develop an effective immune response can still benefit from the antibodies present in the plasma of recovered patients from COVID-19, especially in the early stages of the disease
    .

    This is definitely something worth investigating
    .

    "Researchers are not sure why the recovery period plasma can not improve significantly.
    The condition of most critically ill patients
    .

    Co-senior author Dr.
    Derek Angus is also the Chief Innovation Officer of the University of Pittsburgh School of Medicine and the head of the Pete Department of Critical Care Medicine.
    He explained: “We speculate that this may be due to too few high-quality antibodies in the plasma and the patient’s disease progression for too long.
    The inflammatory immune response is out of control, and these antibodies cannot reverse the situation.
    Convalescent plasma may still help people in the early stages of the disease, despite the fact that the monoclonal antibody evaluated by the University of Pittsburgh School of Medicine in our OPTIMISE-C19 adaptability test is an early new coronavirus 19 effective treatment methods, using this plasma may not be effective
    .

    "Reference: https://medicalxpress.
    com/news/2021-10-convalescent-plasma-futile-treatment-critical.
    html Note: This article aims to introduce Medical research progress cannot be used as a reference for treatment options
    .

    If you need health guidance, please go to a regular hospital
    .

    Popular·Article Tumor Research [Science] Protein may become a new breakthrough in cancer treatment! New Coronavirus [Science] The truth about the source of SARS-CoV-2? The coronavirus that is the closest to the new coronavirus so far has been found in Lao bats, with a matching rate of 96.
    8%! Environmental health [hot discussion] terrible! It causes the health and high mortality of nearly 15 million infants every year? It's time to be vigilant! Lead poisoning【Jama Sub-Journal】Unexpected! Large-scale study of more than 1.
    1 million people: Lead was detected in half of children's blood! Lead is endangering life and health.
    The new crown virus [The BMJ] has an inoculation rate of 78% in Israel.
    Why is the epidemic still out of control? Is there a need to worry about the effectiveness of the new crown vaccine? Is it necessary to strengthen the injection? Organoid Research [Nature Sub-Journal] A 3D pancreatic cancer tumor model cultivated by an international team of scientists including Shanghai Jiaotong University can effectively improve the treatment of pancreatic cancer.
    Tumor Research [Science Sub-Journal] Salt has the effect of inhibiting tumors ? Scientists explain unexpected discoveries for you through mouse experiments! Recommendation·Activity The 5th Symposium on Modern Clinical Molecular Diagnosis at the 3rd Shanghai International Cancer Conference
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.